Global Allogeneic Stem Cells Market - 2023-2030

Global Allogeneic Stem Cells Market - 2023-2030

The Global Allogeneic Stem Cells Market size reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.0 billion by 2030. The global allogeneic stem cells market is expected to exhibit a CAGR of 9.6% during the forecast period (2023-2030). The ongoing clinical trials and collaborations are driving up demand for allogeneic stem cells market trends.

The allogeneic stem cells market has witnessed significant growth and development in recent years. Allogeneic stem cells have the potential to differentiate into various cell types and hold great promise for treating a wide range of chronic diseases and conditions. Additionally, the rising demand for personalized medicine and the availability of government funding and support for stem cell research are contributing to the market's expansion.

The global allogeneic stem cells market is driven by the factors such as the increasing prevalence of cardiovascular disorders, cancer diseases, and other chronic disorders, increasing awareness and acceptance of stem cell therapies, increasing research and development activities on allogeneic stem cells, rising demand for regenerative medicines, and technological advancements in allogeneic stem cell transplantation.

Market Dynamics

Rising Demand for Regenerative Medicines Drives the Growth of the Allogeneic Stem Cells Market

The prevalence of chronic diseases, such as cardiovascular disorders, neurodegenerative conditions, orthopedic injuries, and autoimmune diseases, is on the rise globally. Regenerative medicine, including allogeneic stem cell therapies, offers innovative and promising treatment options for these challenging conditions, driving the demand for such advanced therapies.

Rapid advancements in stem cell research and tissue engineering technologies have significantly enhanced the understanding of stem cell biology and the development of effective regenerative therapies. These technological breakthroughs have expanded the possibilities and applications of allogeneic stem cells, contributing to the market's growth.

For instance, on September 06, 2022, according to the Food and Drug Administration (FDA), a regenerative medicine therapy is a 3D-printed scaffold made of a new biomaterial with cells derived from allogeneic stem cells in vitro. Scaffolds allow multiple cell types to grow on a single implant to speed up tissue growth.

Increasing Awareness and Acceptance of Stem Cells Therapies Also Drive the Growth of the Market

Stem cell therapies offer promising outcomes in various fields, including regenerative medicine, oncology, neurology, cardiology, and orthopedics. Clinical trials and real-world evidence have demonstrated the potential of stem cells to regenerate damaged tissues, promote healing, modulate the immune system, and provide novel approaches to treating previously incurable conditions. As positive treatment outcomes become more widely known, the acceptance of stem cell therapies grows.

The acceptance of stem cell therapies among healthcare providers and physicians is also crucial in driving market growth. As medical professionals gain confidence in the safety, efficacy, and appropriate use of stem cell therapies, they are more likely to recommend and incorporate these treatments into their practice. Increased adoption by healthcare providers leads to broader access to stem cell therapies for patients.

Stringent Pricing of Allogeneic Stem Cell Transplantation Will Hamper the Growth of the Market

High pricing creates barriers to access for patients who may require allogeneic stem cell transplantation as a treatment option. The cost-intensive nature of the procedure, including donor matching, pre-transplant conditioning, transplantation process, post-transplant care, and follow-up, can make it financially unattainable for many individuals, especially in regions with limited healthcare resources or inadequate insurance coverage.

Stringent pricing can impact the overall investment in research and development in the field of allogeneic stem cell transplantation. Pharmaceutical companies, biotechnology firms, and academic institutions may face challenges in funding and conducting research, developing innovative therapies, and advancing the field. This slows down the development of new treatment options and limit the expansion of the market.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the allogeneic stem cells market. The pandemic has disrupted global supply chains, including the collection, processing, and transportation of allogeneic stem cells. Restrictions on travel, social distancing measures, and lockdowns have affected the availability of donor cells and the transportation of stem cell products. This disruption in the supply chain has led to delays in treatments and reduced accessibility to allogeneic stem cell transplantation.

Many ongoing clinical trials investigating the use of allogeneic stem cells for various indications have been affected by the pandemic. Enrollment in trials has been challenging, and some trials have been temporarily halted or modified to ensure the safety of participants and healthcare personnel. These disruptions in clinical research may delay the development and commercialization of new therapies.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global allogeneic stem cells market. The conflict can disrupt the supply chain of allogeneic stem cells, particularly if there are restrictions on transportation routes or disruptions in the healthcare infrastructure in the affected regions. This disruption can lead to delays or shortages in the availability of donor cells, affecting the transplantation procedures and overall market supply.

Segment Analysis

The global allogeneic stem cells market is segmented based on product, cell origin, application, and region.

Cord Blood Stem Cells from the Cell Origin Segment Account for 34.9% of the Allogeneic Stem Cells Market Share

The collection of cord blood is a safe and non-invasive procedure that poses no risk to the mother or newborn. This collection process occurs immediately after childbirth, and the storage of cord blood does not involve any ethical concerns. These factors make cord blood collection more acceptable and preferred by parents, leading to a significant supply of cord blood for therapeutic use.

Cord blood stem cells have demonstrated successful clinical outcomes in hematopoietic stem cell transplantation for various hematological disorders, including leukemia, lymphoma, and inherited metabolic disorders. The well-established use of cord blood in these therapeutic areas has solidified its position as a preferred source for allogeneic stem cell transplantation.

For instance, on August 29, 2022, StemCyte, a Southern California cord blood regenerative therapeutics company received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years.

Geographical Analysis

North America Accounted for Approximately 41.6% of the Market Share Owing to the Well-Developed Healthcare Infrastructure and the Presence of Major Players

North America hosts several major players in the field of allogeneic stem cells. Pharmaceutical companies, biotechnology firms, and stem cell banks based in North America have made significant investments in research, development, and commercialization of stem cell therapies. Their expertise, resources, and market presence contribute to the growth and dominance of the region in the allogeneic stem cells market.

For instance, on April 26, 2023, CELL Technologies Inc., a clinical-stage biopharmaceutical company announces the submission of the clinical data of its stem cell program in pain for Health Canada approval. CELL is aiming to become the first regulatory-approved stem cell provider in North America. CELL submitted clinical data from 3 studies on Arthritis, degenerative disc disease, and back pain.

North America, particularly the United States, has a robust and advanced healthcare infrastructure. The region boasts a network of renowned hospitals, research institutions, and specialized healthcare facilities that support the development, manufacturing, and delivery of allogeneic stem cell therapies. The presence of state-of-the-art healthcare facilities enables efficient clinical trials, patient access to treatment, and the integration of stem cell therapies into standard medical practice.

Competitive Landscape

The major global players in the allogeneic stem cells market include STEMCELL Technologies Inc., Lineage Cell Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Biosolution Co. Ltd., Cynata Therapeutics Ltd., JCR Pharmaceuticals Co. Ltd., MEDIPOST Co. Ltd., MiMedx Group Inc., Osiris Therapeutics Inc., and Stempeutics Research Pvt. Ltd.

Why Purchase the Report?
• To visualize the global allogeneic stem cells market segmentation based on product, cell origin, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of allogeneic stem cells market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global allogeneic stem cells market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies